LOGIN  |  REGISTER

Azenta to Participate in Upcoming Investor Conferences

February 28, 2023 | Last Trade: US$50.00 0.00 0.00

BURLINGTON, Mass., Feb. 28, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in two upcoming investor conferences:

  • Cowen 43rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7th, 2023. Includes a presentation beginning at 12:50 pm ET
  • Barclays Global Healthcare Conference in Miami, FL, on Wednesday, March 15th, 2023. Includes a presentation beginning at 3:35 pm ET

The live webcast of the presentations can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the events.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Sara Silverman
Head of Investor Relations & Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Sherry Dinsmore
This email address is being protected from spambots. You need JavaScript enabled to view it.

Azenta logo (PRNewsfoto/Azenta)

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB